Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will be home in about an hour,
will send then
Joe K
Ez,
I've sent you an email.
Thanks,
Joe K.
I think the filing was on Sept 24th.
They have 30 days after they have been served and a return of service is made available to the court by the process server. The filing was on OCT 24, the serving that we don't know.
Sign me up!
Wook,
Send me your email -
I want to share something with you.
Joe K.
Loof,
Just like the last time.
Somebody knows something
that I don't.
This time I hope it doesn't stop.
Joe K.
When all of this is over.
You can say that you really
worked for that money!
Loof,
I stand corrected.
I guess it is a pump!
Thanks,
Joe K.
Usually see a pump.
Don't see it anywhere.
No News.
Not even Sierra.
Joe K.
Sent,
Thanks.
Loof,
Did you get my email?
Joe K.
You do hold on to a thought!
Ez,
Can you pm me an email address.
I'd like to share something with you
and get your opinion.
Thanks,
Joe K.
More_people_are_selling_than_buying.
Cloaked, Keep up the good work.
Thanks.
Joe K.
Unless you can come up with a link
it should be IMO.
Don't lead us on.
There is enough b/s on both sides.
You are missing the boat!
Any 'professional' who says
"if it seems too good to be true it probably is"
Is making a subjective opinion.
Any professional deeply involved in his own
project will subjectively dismiss all that is
not his.
Is that you Mike?
Did someone get a hold of your keyboard?
Some people just hate this company.
They use this to justify their positions.
If it's there and restricted
couldn't you just buy and not sell
until it settles?
Alvaroc,
I do not have a bloomberg terminal
so your info is important to me.
Thanks,
Joe K.
From the WSJ
Peregrine Pharmaceuticals Inc. (PPHM) filed a lawsuit against a contractor it accused of producing unreliable data in a clinical trial involving the company's cancer drug Bavituximab.
News of the allegedly unreliable data erased more than three-quarters of the value of Peregrine's shares earlier this week and has threatened the company's future.
In the lawsuit, Peregrine accused the contractor--Clinical Supplies Management Inc. of North Dakota--of making errors that led to discrepancies in test results of patients and the treatments they had been assigned.
Clinical Supplies had no comment on the suit, Director of Business Development Jennifer Lauinger said.
Peregrine is seeking unspecified damages, and it notes, "The magnitude of the resulting harm is currently unknown."
This isn't the first time that Clinical Supplies has been accused of distributing the wrong drugs to patients in clinical trials. In a 2011 lawsuit, Merix Pharmaceutical Corp. accused the company of mistakenly distributing an adulterated placebo to patients in a clinical trial of its over-the-counter cold sore treatment Releev.
Peregrine has said it found major discrepancies between some patients' test results and the treatments they received in a study of Bavituximab among lung cancer patients for whom initial treatment doesn't work.
As a result, the company said, investors shouldn't rely on results from earlier this month, which stated that patients who took Bavituximab saw their median overall survival rate double over those who just took chemotherapy. The company has since said that without raising more capital it would have enough money to fund operations only through April.
Shares were down 9% recently to $1.01.
Write to Joseph Walker at Joseph.Walker@dowjones.com
Toga! Toga! Toga!
There was news yesterday.
ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services
Aug 01, 2012
Rockville, MD (August 1, 2012)
- Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff. The contract has a funding potential of up to $102 million over 10 years, subject to availability of annual appropriations.
Real time here.
http://www.nasdaq.com/symbol/pphm/premarket
Recovering a little in premarket on news.
(I think). IMO. FWIW
Advanced BioScience Laboratories Awards Avid Bioservices HIV Vaccine
Development and Manufacturing Contract
Avid Will Provide Development and
Manufacturing Services to Support cGMP Production of an HIV Envelope Protein for
ABL's NIH Funded-NIAID Preclinical Development Support Contract
HHSN272201100021I
Toga! Toga! Toga! Toga!
Funny!
4mil shares up .17 in 7 min.
Ok, lets see what happens if no one responds.
Take the pledge.
1.70 Weeeeeeeeeeeeeeeeeee
Thats what I originally thought
but my Scottrade quote shows 1.70
But I definitly saw 1.73 as the
closing price on L2 and Time and Sales.
I'll take either.
1.70---- Weeeeeeeeeeeeeeeeeeeeeeeeeeee
Another bottom feeder.
Robbins Umeda LLP Announces an Investigation of Peregrine
Pharmaceuticals, Inc.
But you sold, so why
do you care?
Kei,
I can't private reply.
I'm just going by they way its been trading.
It seems the dead cat landed on a trampoline!
There seems to be a lot of buying.
I would guess that this continues up.
But then, I never guessed it would
dump on Monday.
IMO
Best of luck to you.
Joe K.